In the subcutaneous xenograft model using H1975 cells (EGFR Del19/T790M/C797S), we tested the therapeutic efficacy and safety profiles of WX-0593, QL1203, Vectibix, and their combination…the combination of WX-0593 (75 mg/kg, OD) with QL1203 or Vectibix was significantly better than all of the other treatment groups in the control of tumor growth (Figure 2B,2C and Table S1)....WX-0593 exhibited a synergetic effect with an EGFR monoclonal antibody on osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC) both in vitro and in vivo. Their combination showed potent antitumor efficacy and an acceptable safety profile, which may be a promising strategy for the treatment of patients with EGFR triple-mutant NSCLC...